Published in J Infect Dis on January 01, 2009
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis. Lancet Neurol (2010) 4.95
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology (2014) 3.15
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry (2013) 2.23
Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology (2010) 1.97
Determinants of survival in progressive multifocal leukoencephalopathy. Neurology (2009) 1.77
Inclusion of rituximab in treatment protocols for non-Hodgkin's lymphomas and risk for progressive multifocal leukoencephalopathy. Oncologist (2010) 1.26
Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PLoS One (2011) 1.25
JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy. J Cell Physiol (2012) 1.20
Human polyoma viruses and disease with emphasis on clinical BK and JC. J Clin Virol (2010) 1.17
Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol (2011) 1.12
Neurologic presentations of AIDS. Neurol Clin (2010) 1.12
Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy. J Neurol Neurosurg Psychiatry (2010) 1.04
Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord (2015) 1.03
Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol (2013) 0.96
Emerging viral infections of the central nervous system: part 2. Arch Neurol (2009) 0.94
Immune surveillance and response to JC virus infection and PML. J Neurovirol (2013) 0.91
Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV/AIDS patients in the current era. Eur J Clin Microbiol Infect Dis (2013) 0.90
Hyperintense cortical signal on magnetic resonance imaging reflects focal leukocortical encephalitis and seizure risk in progressive multifocal leukoencephalopathy. Ann Neurol (2014) 0.85
Progressive multifocal leukoencephalopathy during treatment with rituximab and CHOP chemotherapy in a patient with a diffuse large B-cell lymphoma. BMJ Case Rep (2013) 0.84
Pseudovirus mimics cell entry and trafficking of the human polyomavirus JCPyV. Virus Res (2013) 0.83
B cells and progressive multifocal leukoencephalopathy: search for the missing link. Front Immunol (2015) 0.82
Unmasking of PML by HAART: unusual clinical features and the role of IRIS. J Neuroimmunol (2009) 0.81
Characteristics of progressive multifocal leukoencephalopathy clarified through internet-assisted laboratory surveillance in Japan. BMC Neurol (2012) 0.80
Progressive multifocal leucoencephalopathy in HIV/AIDS: observational study from a tertiary care centre in northern India. Indian J Med Res (2013) 0.80
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? Clin Dev Immunol (2013) 0.78
Does contrast enhancement predict survival in progressive multifocal leukoencephalopathy? J Infect Dis (2009) 0.77
HIV-associated opportunistic CNS infections: pathophysiology, diagnosis and treatment. Nat Rev Neurol (2016) 0.76
PML therapy: "It's Déjà vu all over again". J Neurovirol (2013) 0.76
Polyomavirus-Specific Cellular Immunity: From BK-Virus-Specific Cellular Immunity to BK-Virus-Associated Nephropathy? Front Immunol (2015) 0.75
Progressive multifocal leukoencephalopathy following chemotherapy for lung cancer. Neurol Sci (2011) 0.75
From Clinical Presentation to the Outcome: the Natural History of PML in a Portuguese Population of HIV Infected Patients. J Clin Med Res (2011) 0.75
Progressive multifocal leukoencephalopathy: cavitary white matter lesions. J La State Med Soc (2013) 0.75
Progressive Multifocal Leukoencephalopathy. F1000Res (2015) 0.75
JC polyomavirus reactivation is common following allogeneic stem cell transplantation and its preemptive detection may prevent lethal complications. Bone Marrow Transplant (2015) 0.75
Neuropathology of JC virus infection in progressive multifocal leukoencephalopathy in remission. World J Virol (2016) 0.75
Progressive multifocal leukoencephalopathy, a rare but devastating disease in AIDS patients. Indian J Med Res (2013) 0.75
Rhodiolae Kirliowii Radix et Rhizoma and Crataegus pinnatifida Fructus Extracts Effectively Inhibit BK Virus and JC Virus Infection of Host Cells. Evid Based Complement Alternat Med (2017) 0.75
Neuropsychological evaluation and follow up in jcv- and non-jcv-related leukoencephalopathies in HIV infection. Neurol Sci (2011) 0.75
Incidence, clinical presentation, and outcome of HIV-1-associated cryptococcal meningitis during the highly active antiretroviral therapy era: a nationwide cohort study. Clin Epidemiol (2017) 0.75
Case report: progressive multifocal encephalopathy (PML) causing an isolated cerebellar syndrome. Neurol Sci (2016) 0.75
A whole-genome association study of major determinants for host control of HIV-1. Science (2007) 15.19
Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis (2011) 7.41
Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med (2007) 6.30
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Syphilis and human immunodeficiency virus (HIV)-1 coinfection: influence on CD4 T-cell count, HIV-1 viral load, and treatment response. Sex Transm Dis (2006) 2.90
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med (2007) 2.85
All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol (2011) 2.80
Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis (2007) 2.69
The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS (2010) 2.51
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Mortality attributable to smoking among HIV-1-infected individuals: a nationwide, population-based cohort study. Clin Infect Dis (2012) 2.39
Low serum mannose-binding lectin level increases the risk of death due to pneumococcal infection. Clin Infect Dis (2008) 2.20
Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Hepatology (2014) 2.17
Macrophage serum markers in pneumococcal bacteremia: Prediction of survival by soluble CD163. Crit Care Med (2006) 2.06
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis (2004) 2.02
Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology (2008) 1.98
Risk of triple-class virological failure in children with HIV: a retrospective cohort study. Lancet (2011) 1.90
Impact of hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study. Clin Infect Dis (2006) 1.87
Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract (2007) 1.86
Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nat Immunol (2009) 1.83
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. AIDS (2009) 1.81
HIV care in the Swedish-Danish HIV cohort 1995-2010, closing the gaps. PLoS One (2013) 1.77
Incidence rate of community-acquired sepsis among hospitalized acute medical patients-a population-based survey. Crit Care Med (2015) 1.75
Development of diagnostic criteria for serious non-AIDS events in HIV clinical trials. HIV Clin Trials (2010) 1.75
Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med (2002) 1.70
Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis (2006) 1.68
Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infect Dis (2011) 1.68
Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS (2011) 1.68
Determination of the underlying cause of death in three multicenter international HIV clinical trials. HIV Clin Trials (2008) 1.65
Risk of cerebrovascular events in persons with and without HIV: a Danish nationwide population-based cohort study. AIDS (2011) 1.57
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection. J Virol (2010) 1.57
Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load. J Infect Dis (2005) 1.56
CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med (2012) 1.54
Expression of fibroblast growth factor-21 in muscle is associated with lipodystrophy, insulin resistance and lipid disturbances in patients with HIV. PLoS One (2013) 1.50
Right and left ventricular cardiac function in a developed world population with human immunodeficiency virus studied with radionuclide ventriculography. Am Heart J (2004) 1.46
Improved survival in HIV-infected persons: consequences and perspectives. J Antimicrob Chemother (2007) 1.45
Emergency department physicians spend only 25% of their working time on direct patient care. Dan Med J (2013) 1.45
Incidence of low and high-energy fractures in persons with and without HIV infection: a Danish population-based cohort study. AIDS (2012) 1.45
Smoking and life expectancy among HIV-infected individuals on antiretroviral therapy in Europe and North America. AIDS (2015) 1.44
K65R with and without S68: a new resistance profile in vivo detected in most patients failing abacavir, didanosine and stavudine. Antivir Ther (2003) 1.42
Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One (2011) 1.42
[Administration of medications. Joint charts for prescription--transcription and dispensing errors]. Ugeskr Laeger (2004) 1.40
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Effect of hyperglycemia and hyperinsulinemia on the response of IL-6, TNF-alpha, and FFAs to low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab (2004) 1.38
Calprotectin--a marker of mortality in COPD? Results from a prospective cohort study. COPD (2013) 1.38
Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis (2011) 1.37
The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS (2006) 1.37
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35
Procalcitonin, lipopolysaccharide-binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study. Crit Care (2006) 1.34
Demographics of HIV-1 infection in Denmark: results from the Danish HIV Cohort Study. Scand J Infect Dis (2005) 1.33
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Aetiology and prediction of pneumonia in lower respiratory tract infection in primary care. Br J Gen Pract (2007) 1.32
Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Euro Surveill (2015) 1.29
Loss to follow-up occurs at all stages in the diagnostic and follow-up period among HIV-infected patients in Guinea-Bissau: a 7-year retrospective cohort study. BMJ Open (2013) 1.29
Reporting and evaluation of HIV-related clinical endpoints in two multicenter international clinical trials. HIV Clin Trials (2006) 1.27
Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis (2003) 1.25
Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery. Clin Infect Dis (2014) 1.25
Low mortality in HIV-infected patients starting highly active antiretroviral therapy: a comparison with the general population. AIDS (2004) 1.24